Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in long-term preventive therapy.

M Schou

    Psychopathology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Lowering serum lithium levels to 0.5-0.8 mmol/l significantly reduces side effects and increases safety. Antidepressants or other mood stabilizers like carbamazepine and valproate offer alternatives for specific patient groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Return to work after COVID-19 infection - A Danish nationwide registry study.

    Public health·2022
    Same author

    Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort.

    Journal of internal medicine·2021
    Same author

    Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic.

    International journal of cardiology. Heart & vasculature·2020
    Same author

    Preheart failure comorbidities and impact on prognosis in heart failure patients: a nationwide study.

    Journal of internal medicine·2020
    Same author

    Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes.

    Diabetes & metabolism·2018
    Same author

    Prevalence of serum anti-neuronal autoantibodies in patients admitted to acute psychiatric care.

    Psychological medicine·2016
    Same journal

    Tourette syndrome and rage attacks - a longitudinal and cross-sectional study.

    Psychopathology·2026
    Same journal

    Depressing temporal experiences: the COVID-19 Pandemic lockdown in Victoria, Australia.

    Psychopathology·2026
    Same journal

    Involuntary hospitalization for treatment: Triangulation of Perspectives of patients, relatives, and professionals.

    Psychopathology·2026
    Same journal

    Depersonalization, Emotion Embodiment, and Alexithymia in the General Population.

    Psychopathology·2026
    Same journal

    Symptom course in psychiatric and neurodevelopmental diagnostic reasoning: an exploratory vignette-based study.

    Psychopathology·2026
    Same journal

    Operationalizing the Whole of Psychic Life: Toward a Structured Framework for Psychopathology.

    Psychopathology·2026
    See all related articles

    Area of Science:

    • Psychiatry
    • Pharmacology
    • Neuroscience

    Background:

    • Lithium is a cornerstone mood stabilizer for bipolar disorder.
    • Standard lithium levels may be associated with significant side effects.
    • Alternative treatments are needed for patients intolerant or unresponsive to lithium.

    Purpose of the Study:

    • To evaluate the impact of reduced serum lithium levels on efficacy and safety.
    • To explore alternative maintenance therapies for unipolar and bipolar depression.
    • To discuss long-term preventive treatment strategies for mood disorders.

    Main Methods:

    • Review of existing literature on lithium therapy and alternative treatments.
    • Analysis of safety data associated with different lithium serum concentrations.

    Related Experiment Videos

  • Comparison of antidepressant and mood stabilizer efficacy in specific patient populations.

    • Main Results:

    • Reduced serum lithium levels (0.5-0.8 mmol/l) markedly decrease side effects.
    • Temporary lithium discontinuation or dose reduction enhances safety in high-risk situations.
    • Antidepressants are a viable alternative to lithium for unipolar patients; carbamazepine and valproate are options for lithium-refractory bipolar patients.

    Conclusions:

    • Optimizing lithium serum levels improves patient safety and tolerability.
    • Individualized treatment selection, considering alternatives, is crucial for long-term mood disorder management.
    • Carbamazepine and valproate show promise for specific bipolar patient subgroups.